Investor Presentation on financial results for the quarter and financial year ended March 31, 2026
BOROSCI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Borosil Scientific Ltd reported strong Q4FY26 consolidated results with net sales of Rs 143.2 crore (up 10.6% YoY) and EBITDA of Rs 32.4 crore (up 87.6% YoY), with EBITDA margin expanding to 22.7% from 13.4% in Q4FY25. For full year FY26, consolidated net sales grew 6.6% to Rs 467.3 crore while PAT jumped 29.4% to Rs 34.6 crore. The Scientific Segment (dominating at Rs 330.9 crore) saw strong growth in Lab Equipment (25.6%), though Process Systems declined 11.6% due to deferred high-value orders. The company set medium-term targets of 12-14% revenue CAGR with focus on improving EBITDA margins through high-margin Process Sciences and Lab Equipment segments, plus annual pricing strategies. One-time exceptional items of Rs 8.53 crore included VRS expenses at the Ambad plant.
Strong margin expansion and profitability growth signal operational efficiency gains. The management guidance of 12-14% revenue CAGR and margin improvement focus should be positive for shareholder sentiment, though the Process Systems segment weakness and one-time VRS costs warrant monitoring.